产品号 #70034_C
冻存的人原代细胞
Save on high-quality cells! Take advantage of our bulk pricing discounts and price matching offer to get the best value for your purchase. Browse our Frequently Asked Questions for more information.
通过免疫磁珠负选从单核细胞（MNCs）中分离人外周血原代单核细胞。单核细胞未被标记，可立即用于下游应用。PB采集过程中添加酸-柠檬酸-葡萄糖溶液A作为抗凝剂（ACDA）。
细胞采集均通过机构审查委员会（IRB）批准的知情同意书及方案进行。
某些产品仅在特定地区出售。请与您当地的销售代表或产品与科学支持联系techsupport@stemcell.com获取更多信息。
欲了解更多信息，请浏览有关原代细胞的常见问题解答（FAQs）。
细胞采集均通过机构审查委员会（IRB）批准的知情同意书及方案进行。
某些产品仅在特定地区出售。请与您当地的销售代表或产品与科学支持联系techsupport@stemcell.com获取更多信息。
欲了解更多信息，请浏览有关原代细胞的常见问题解答（FAQs）。
Data Figures
Protocols and Documentation
Find supporting information and directions for use in the Product Information Sheet or explore additional protocols below.
Applications
This product is designed for use in the following research area(s) as part of the highlighted workflow stage(s). Explore these workflows to learn more about the other products we offer to support each research area.
Resources and Publications
Educational Materials (3)
Publications (5)
Rational Drug Design of Topically Administered Caspase 1 Inhibitors for the Treatment of Inflammatory Acne. Journal of medicinal chemistry 2018 MAY
Abstract
The use of an interleukin beta$ antibody is currently being investigated in the clinic for the treatment of acne, a dermatological disorder affecting 650M persons globally. Inhibiting the protease responsible for the cleavage of inactive pro-IL1beta$ into active IL-1beta$, caspase-1, could be an alternative small molecule approach. This report describes the discovery of uracil 20, a potent (38 nM in THP1 cells assay) caspase-1 inhibitor for the topical treatment of inflammatory acne. The uracil series was designed according to a published caspase-1 pharmacophore model involving a reactive warhead in P1 for covalent reversible inhibition and an aryl moiety in P4 for selectivity against the apoptotic caspases. Reversibility was assessed in an enzymatic dilution assay or by using different substrate concentrations. In addition to classical structure-activity-relationship exploration, topical administration challenges such as phototoxicity, organic and aqueous solubility, chemical stability in solution, and skin metabolic stability are discussed and successfully resolved.
Discovery of GS-9973, a selective and orally efficacious inhibitor of spleen tyrosine kinase. Journal of medicinal chemistry 2014 MAY
Abstract
Spleen tyrosine kinase (Syk) is an attractive drug target in autoimmune, inflammatory, and oncology disease indications. The most advanced Syk inhibitor, R406, 1 (or its prodrug form fostamatinib, 2), has shown efficacy in multiple therapeutic indications, but its clinical progress has been hampered by dose-limiting adverse effects that have been attributed, at least in part, to the off-target activities of 1. It is expected that a more selective Syk inhibitor would provide a greater therapeutic window. Herein we report the discovery and optimization of a novel series of imidazo[1,2-a]pyrazine Syk inhibitors. This work culminated in the identification of GS-9973, 68, a highly selective and orally efficacious Syk inhibitor which is currently undergoing clinical evaluation for autoimmune and oncology indications.
Design of a novel integration-deficient lentivector technology that incorporates genetic and posttranslational elements to target human dendritic cells. Molecular therapy : the journal of the American Society of Gene Therapy 2014 MAR
Abstract
As sentinels of the immune system, dendritic cells (DCs) play an essential role in regulating cellular immune responses. One of the main challenges of developing DC-targeted therapies includes the delivery of antigen to DCs in order to promote the activation of antigen-specific effector CD8 T cells. With the goal of creating antigen-directed immunotherapeutics that can be safely administered directly to patients, Immune Design has developed a platform of novel integration-deficient lentiviral vectors that target and deliver antigen-encoding nucleic acids to human DCs. This platform, termed ID-VP02, utilizes a novel genetic variant of a Sindbis virus envelope glycoprotein with posttranslational carbohydrate modifications in combination with Vpx, a SIVmac viral accessory protein, to achieve efficient targeting and transduction of human DCs. In addition, ID-VP02 incorporates safety features in its design that include two redundant mechanisms to render ID-VP02 integration-deficient. Here, we describe the characteristics that allow ID-VP02 to specifically transduce human DCs, and the advances that ID-VP02 brings to conventional third-generation lentiviral vector design as well as demonstrate upstream production yields that will enable manufacturing feasibility studies to be conducted.
更多信息
| Species | Human |
|---|---|
| Contains | • CryoStor® CS10 |
| Purity | ≥ 85% CD14+ by flow cytometry |
| Cell And Tissue Source | Peripheral Blood |
| Donor Status | Normal |
相关产品
-
EasySep™人单核细胞富集试剂盒未接触人单核细胞的免疫磁阴性分离
-
抗人CD14抗体克隆M5E2小鼠抗人、恒河猴、食蟹虫CD14单克隆IgG2a抗体
-
冻存的人外周血CD14+单核细胞冻存的人原代细胞
-
人外周血巨噬细胞，冷冻原代人细胞，冷冻
PRODUCTS ARE FOR RESEARCH USE ONLY AND NOT INTENDED FOR HUMAN OR ANIMAL DIAGNOSTIC OR THERAPEUTIC USES UNLESS OTHERWISE STATED. FOR ADDITIONAL INFORMATION ON QUALITY AT STEMCELL, REFER TO WWW.STEMCELL.COM/COMPLIANCE.
